Ganglion Resection Effectiveness Trial

Summary

The goal of this clinical trial is to learn if surgery helps with wrist ganglions in adults. The main question it aims to answer is:

* Does surgery result in better patient-reported outcomes and satisfaction over a 6-months follow-up period?

Researchers will compare surgery to conservative treatment (self-administered exercises and use of the hand as tolerated) to see if surgery provides superior outcomes.

Participants will:

* Be randomly assigned to receive either surgery or conservative treatment
* Complete questionnaires about wrist pain, function, quality of life, satisfaction, and recovery at 3, 6, and 12 months

Conditions

• Wrist Ganglion
• Ganglion
• Ganglion Cyst
• Connective Tissue Disease
• Mucinoses

Interventions

PROCEDURE

Open resection

A transverse or longitudinal incision is done depending on surgeon's preference. The ganglion and its pedicle are traced up to its origin. The pedicle is resected tangentially, usually, from the SL ligament for dorsal ganglions and depending on the site for volar ganglion. Wrist capsule is not closed.

PROCEDURE

Arthroscopic resection

Portals are selected by surgeon's preference. The pedicle of the ganglion is located and resected with a shaver. It is not necessary to remove all the ganglion walls. The portal incisions do not need to be sutured.

OTHER

Conservative treatment

Participant will be informed about the natural course of wrist ganglions. The conservative treatment may include needle aspiration of the ganglion, but it is not performed routinely. Participants are informed that wrist loading in extension may exacerbate the pain, and that the pain is not a sign of further injury to wrist joint. They can avoid heavy use it if they have too much pain, but they are advised to use hand as tolerated. Participants may use NSAIDs and acetaminophen for pain management as needed; however, the protocol does not specify a required course or dosage. A simple self-implemented exercise therapy instructions are given to every participant.

Sponsors & Collaborators

• Tampere University

  collaborator OTHER

• Hospital Nova of Central Finland

  collaborator UNKNOWN

• National University Hospital, Singapore

  collaborator OTHER

• Helsinki University Central Hospital

  collaborator OTHER

• Tampere University Hospital

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-01-13

Primary Completion

2034-12-31

Completion

2035-12-31

Countries

• Finland
• Singapore

Study Locations